Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | CDK4 | P11802 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCND2 | P30279 | 1/20 | 0.51 |
| ▸ | CCND3 | P30281 | 1/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1353652 | 0.91 | CDK4 (0.54) | MAPTKDM4EHTTEIF2AK4ALDH1A1 | |
| SCHEMBL1355878 | 0.91 | EIF2AK4 (0.49) | MAPTKDM4EHTTEIF2AK4ALDH1A1 | |
| SCHEMBL1355771 | 0.89 | EIF2AK4 (0.64) | MAPTKDM4EHTTEIF2AK4ALDH1A1 | |
| SCHEMBL1355529 | 0.86 | EIF2AK4 (0.53) | MAPTKDM4EEIF2AK4ALDH1A1MEN1 | |
| SCHEMBL1355283 | 0.85 | EIF2AK4 (0.52) | MAPTKDM4EEIF2AK4ALDH1A1MEN1 | |
| SCHEMBL1353796 | 0.84 | EIF2AK4 (0.53) | MAPTKDM4EHTTEIF2AK4ALDH1A1 | |
| SCHEMBL1353632 | 0.84 | EIF2AK4 (0.50) | MAPTKDM4EHTTEIF2AK4ALDH1A1 | |
| SCHEMBL1353635 | 0.84 | EIF2AK4 (0.66) | MAPTKDM4EEIF2AK4ALDH1A1MEN1 | |
| SCHEMBL1355678 | 0.83 | TUBB4A (0.48) | MAPTHTTEIF2AK4ALDH1A1MEN1 | |
| SCHEMBL1356046 | 0.82 | FLT3 (0.54) | EIF2AK4ALDH1A1MEN1KMT2ACDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | claimed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | claimed |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2108020-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008094602-A2 | 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249067-A1 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | MAPT 733/4885KDM4E 1954/4885HTT 4382/4885 |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | MAPT 733/4885KDM4E 1954/4885HTT 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.